A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Malaria Prophylaxis

Interventions

DRUG

azithromycin (AZ) microsphere

AZ microsphere (2000 mg) single dose on Day 1.

DRUG

test chloroquine (CQ) formulation

Test CQ formulation, 620 mg CQ base, single dose on Day 1.

DRUG

azithromycin (AZ)

AZ IR 4 x 500 mg tablets, single dose on Day 1.

DRUG

chloroquine (CQ)

CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1

Trial Locations (1)

Pfizer Investigational Site, New Haven